

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



160 Health International Limited

健康 160 国际有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

VOLUNTARY ANNOUNCEMENT — LATEST PROGRESS ON BUSINESS CONTRACT SIGNING

This announcement is made by 160 Health International Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company of the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that, from January 2025 to March 31, 2026 (the “**Cumulative Period**”), the Group has continued to make significant progress in the digital healthcare and wellness solutions business sector, particularly with the “160AI Hospital” operational collaboration model. During the Cumulative Period, the cumulative number of public medical institutions with which the Group has entered into operational collaboration reached 102.

Details of the business progress are as follows:

I. NUMBER AND STRUCTURE OF PARTNER MEDICAL INSTITUTIONS

During the Cumulative Period, the cumulative number of public medical institutions that have entered into operational collaboration with the Group reached 102, representing a further, steady increase from 82 as at the end of 2025. Notably, 54 are Class IIIA hospitals, accounting for approximately 52.9%, and a total of 78 are Class III or above, accounting for approximately 76.5%. This fully demonstrates the extensive recognition and deep penetration of the Group’s “160AI Hospital” operational collaboration model within the high-end medical system.

II. OPERATIONAL SCALE OF PARTNER HOSPITALS

The overall operational scale of the aforementioned partner hospitals is significant, with a total annual outpatient volume of approximately 84.37 million and total annual revenue of approximately RMB99.7 billion¹. Such data reflects the extensive service capacity and market influence of the partner medical institutions, establishing a solid foundation for the continuous empowerment of the Group's digital healthcare and wellness solutions.

III. BUSINESS MODEL AND STRATEGIC SIGNIFICANCE

The aforementioned collaborations are all based on the innovative "160AI Hospital" operational collaboration business model launched by the Group. As one of the core products of the Group's digital healthcare and wellness solutions business, this model has successfully transitioned from pilot promotion to large-scale implementation. This represents a significant milestone for the Group in empowering the digital transformation of medical institutions and advancing the intelligent upgrading of medical services.

On this basis, the Group is accelerating the deployment of the "Medical Digital Staff" system for partner hospitals, promoting the comprehensive integration of multi-agent systems into medical scenarios, and helping hospitals usher in a new era of smart healthcare powered by advanced AI capabilities. The Group will continue to deepen the national layout of the "160AI Hospital" operational collaboration model, further expand the network of partner medical institutions, enhance the depth and breadth of products and services, and continuously drive the high-quality development of its digital healthcare and wellness business.

The Board wishes to emphasize that the latest business progress disclosed in this announcement only reflects the performance of certain business segments of the Company and does not represent the overall business performance of the Company, and that future business development is subject to uncertainties arising from various factors, including market conditions, industrial policies and actual implementation. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, April 21, 2026

¹ The above data is based on a comprehensive compilation of publicly available information and information provided by partner hospitals.

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin and Ms. SUN Meng as non-executive Directors; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.